May 26, 2022 – The investigational schizophrenia treatment xanomeline/trospium (KarXT) yielded significantly greater improvements in all five Positive and Negative Syndrome Scale (PANSS) Marder factors versus placebo, according to the phase II EMERGENT-1study. These improvements were significant by week 2 of treatment, and included positive and negative symptoms, disorganized thought, uncontrolled hostility, and depression/anxiety.
In the 5-week randomized trial among 170 inpatients with schizophrenia, those treated with a maximum of 125 mg/30 mg twice daily also had significant improvements in Clinical Global Impressions Scale categorical responses as early as week 2 of treatment.
“If confirmed in ongoing phase 3 studies and approved by the [FDA], KarXT may represent a novel class of treatment for patients with schizophrenia based on muscarinic receptor agonism,” Christoph Correll, MD, of the Zucker Hillside Hospital in Glen Oaks, New York, and colleagues said in an APA poster.
GIVING BACK IN STYLE – April 17, 2024 - “It’s still one day at…
RIDING THE WAVE...CALMLY – April 18, 2024 - “I was 13 years old and…
VIDEO – NEW YORK STORIES – April 23, 2024 - Sara Gettelfinger had steadily…
TRY IT, YOU’LL LIKE IT – April 18, 2024 - The rise in “sober…
AUDIO – SOBER MEN CAN DO THAT – April 4, 2024 - Acting icon…
I’LL BET HE GOES TO GA (not Georgia) – April 13, 2024 -The initial…